Analysts Set Thermo Fisher Scientific Inc. (NYSE:TMO) PT at $630.41

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have earned an average rating of “Moderate Buy” from the eighteen analysts that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $630.41.

A number of analysts have recently weighed in on the company. Robert W. Baird raised their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. TD Cowen boosted their target price on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Stifel Nicolaus upped their price objective on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Royal Bank of Canada lifted their target price on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at $7,860,920.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TMO. International Assets Investment Management LLC grew its stake in Thermo Fisher Scientific by 17.0% in the fourth quarter. International Assets Investment Management LLC now owns 1,902 shares of the medical research company’s stock valued at $1,010,000 after purchasing an additional 276 shares in the last quarter. GUNN & Co INVESTMENT MANAGEMENT INC. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth $253,000. Silver Oak Securities Incorporated bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $240,000. MONECO Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 41.0% during the 4th quarter. MONECO Advisors LLC now owns 994 shares of the medical research company’s stock worth $528,000 after purchasing an additional 289 shares during the last quarter. Finally, Alpha Cubed Investments LLC raised its holdings in shares of Thermo Fisher Scientific by 7.0% in the 4th quarter. Alpha Cubed Investments LLC now owns 639 shares of the medical research company’s stock valued at $339,000 after purchasing an additional 42 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $606.65 on Friday. The business has a 50 day simple moving average of $580.69 and a 200 day simple moving average of $577.10. Thermo Fisher Scientific has a one year low of $415.60 and a one year high of $622.30. The company has a market capitalization of $231.74 billion, a PE ratio of 38.91, a price-to-earnings-growth ratio of 2.86 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping the consensus estimate of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company’s revenue was down 1.4% on a year-over-year basis. During the same quarter last year, the business posted $5.15 earnings per share. On average, sell-side analysts forecast that Thermo Fisher Scientific will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.